EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in AURA-2, a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2026.06.16

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2019-03-12

FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively

2019-01-10

The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award

2018-10-30

Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics

2018-10-29

Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018

2018-08-22

Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China

2018-08-10

Group Turnover and Profit in the First Half of 2018 Increased 28.3%

2018-07-24

Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis

2018-07-18

Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT